$595m octreotide deal grabs Roche


Swiss drugmaker Roche has struck a $595 million (£390 million) deal with US firm Chiasma for Octreolin (octreotide) tablets for treating acromegaly, a rare condition that causes excessive growth.

The active compound, octreotide, is already commercially available as an injection, marketed by Novartis under the name Sandostatin. The tablets are currently in Phase III trials against acromegaly, which is caused by the pituitary gland producing too much growth hormone. The two companies will subsequently look to commercialise the drug for the treatment of neuroendocrine tumours.

Roche will pay $65 million for worldwide marketing rights to the brand and make further payments of up to $530 million as milestones are passed.

Chiasma specialises in turning injectable drug formulations into viable oral equivalents.


Related Content

From molecules to medicines

9 April 2013 Premium contentFeature

news image

Turning an active drug molecule into a finished product requires a lot of chemistry, as Phillip Broadwith discovers

Business roundup

26 October 2011 Business

news image

Industry news, November 2011

Most Commented

How to print a crystal in 3D

17 April 2014 Research

news image

Rather than looking at a crystal on a screen, print it out and hold it in your hand

The sultan of synthesis

11 April 2014 Feature

news image

Phil Baran is spurring organic chemists to rethink how they make complex compounds, as Mark Peplow discovers